WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838 - 29 June 2022

Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

Zhongyi Mu^*†1, Dan Dong^*1, Ning Wei^‡§, Mingli Sun^¶, Wei Wang^*, Yue Shao^*, Jian Gao^*, Ping Yin^*, Chenghai Zhao^*

Oncology Research, Vol.27, No.6, pp. 653-661, 2019, DOI:10.3727/096504018X15420748671075

Abstract The lncRNA AFAP1-AS1, oriented from an antisense direction to the protein-coding gene AFAP1 in the opposite strand, was upregulated in a variety of tumors and associated with poor prognosis, including lung cancer, breast cancer, ovarian cancer, and so on. However, the biological role of AFAP1-AS1 in clear cell renal cell carcinoma (ccRCC) is still unknown. We observed that AFAP1-AS1 expression was significantly upregulated in ccRCC tissues and that patients with high-level expression of AFAP1-AS1 had a shorter overall survival. Knockdown of AFAP1-AS1 markedly suppressed the progression of proliferation, invasion, migration, and EMT in ccRCC cells.… More >

Kun Fan^1,2, Xiaofu Qiu², Yu Fu², Kangjian Lin, Huanhui Li², Guosheng Yang ^*,1,2

Molecular & Cellular Biomechanics, Vol.14, No.1, pp. 33-45, 2017, DOI:10.3970/mcb.2017.014.035

Abstract This study intends to investigate the role of amentoflavone(AF) in human clear-cell renal cell carcinoma (ccRCC) and to elucidate underlying molecular mechanisms. Materials and Methods: Human RCC cell lines Caki-1 and 786-O were used in this study. Cell proliferation, apoptosis, cell cycle distribution and invasion assays were conducted to analyze the effect of AF against ccRCC in vitro. Xenograft model and pulmonary metastasis animal model were established to evaluate the vivo therapeutic efficacy and against pulmonary metastasis ability of AF, respectively. Results: Our findings revealed that AF selectively suppressed tumor cell proliferation in a dose- and More >